Malpique R.,Institute dInvestigations Biomediques August Pi i Sunyer IDIBAPS |
Malpique R.,Research Center Biomedica En Red Of Diabetes fermedades Metabolicas Asociadas |
Figueiredo H.,Institute dInvestigations Biomediques August Pi i Sunyer IDIBAPS |
Figueiredo H.,Research Center Biomedica En Red Of Diabetes fermedades Metabolicas Asociadas |
And 18 more authors.
Diabetologia | Year: 2014
Aims/hypothesis: Comprehensive characterisation of the interrelation between the peripancreatic adipose tissue and the pancreatic islets promises novel insights into the mechanisms that regulate beta cell adaptation to obesity. Here, we sought to determine the main pathways and key molecules mediating the crosstalk between these two tissues during adaptation to obesity by the way of an integrated inter-tissue, multi-platform analysis. Methods: Wistar rats were fed a standard or cafeteria diet for 30 days. Transcriptomic variations by diet in islets and peripancreatic adipose tissue were examined through microarray analysis. The secretome from peripancreatic adipose tissue was subjected to a non-targeted metabolomic and proteomic analysis. Gene expression variations in islets were integrated with changes in peripancreatic adipose tissue gene expression and protein and metabolite secretion using an integrated inter-tissue pathway and network analysis. Results: The highest level of data integration, linking genes differentially expressed in both tissues with secretome variations, allowed the identification of significantly enriched canonical pathways, such as the activation of liver/retinoid X receptors, triacylglycerol degradation, and regulation of inflammatory and immune responses, and underscored interaction network hubs, such as cholesterol and the fatty acid binding protein 4, which were unpredicted through single-tissue analysis and have not been previously implicated in the peripancreatic adipose tissue crosstalk with beta cells. Conclusions/interpretation: The integrated analysis reported here allowed the identification of novel mechanisms and key molecules involved in peripancreatic adipose tissue interrelation with beta cells during the development of obesity; this might help the development of novel strategies to prevent type 2 diabetes. © 2014 Springer-Verlag Berlin Heidelberg.
Fundacio Institute Dinvestigacio Biomedica Of Bellvitge Idibell, Ciber Enfermedades Respiratorias and Fundacio Institute Of Recerca Hospital Universitari Vall Dhebron | Date: 2012-11-23
The present invention relates to mesenchymal stem cells (MSC) genetically modified to express sST2 or parts thereof for use in the treatment of airway immune inflammatory and lung diseases, wherein said mesenchymal stem cells are not human embryonic stem cells. The present invention also relates to pharmaceutical compositions comprising said mesenchymal stem cells.
Fundacio Institute Dinvestigacio Biomedica Of Bellvitge Idibell, Fondation Ela, Catalan Institution for Research and Advanced Studies | Date: 2013-03-13
The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy.
Fundacio Institute Dinvestigacio Biomedica Of Bellvitge Idibell | Date: 2012-07-16
The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells.
Fundacio Institute Dinvestigacio Biomedica Of Bellvitge Idibell | Date: 2013-08-12
The present invention relates to methods for determining the probability of transplant rejection based on the determination in the subject recipient of the transplant of the levels of antibodies specific for hyaluronic acid. The invention relates as well to methods for attenuating transplant rejection and compositions to prevent transplant rejection based on the depletion of anti-hyaluronic acid antibodies from the subject.
Fundacio Institute Dinvestigacio Biomedica Of Bellvitge Idibell | Date: 2012-09-07
The present invention is related to methods for prevention and/or treatment of a number of diseases, such as lupus nephritis, ischemia/reperfusion injury and sepsis, based on the silencing of CD40 using different RNA silencing strategies.